Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF6UP7
|
|||
| Drug Name |
Tadekinig alfa
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | XIAP deficiency [ICD-11: 4A01.22] | Phase 3 | [1] | |
| Company |
AB2 Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-18 (IL18) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NOD-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Salmonella infection | ||||
| Legionellosis | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| Tuberculosis | ||||
| Influenza A | ||||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Toll receptor signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL12-mediated signaling events | ||||
| IL23-mediated signaling events | ||||
| Cellular roles of Anthrax toxin | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Interleukin-1 processing | |||
| WikiPathways | Hypertrophy Model | |||
| IL1 and megakaryotyces in obesity | ||||
| Corticotropin-releasing hormone | ||||
| NOD pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03512314) Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AB2 Bio. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.